Should the Front Office-Back Office Divide End? 
Durabook Introduces the R12 Rugged Tablet Active Edge AI Platform 
IronSight AI and Fast Iron Partner to Bring AI-Powered Inventory Capture to Caterpillar, Komatsu and Volvo Equipment Dealers Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE,…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
ORYZON Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders
A highly selective HDAC-6 inhibitor Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model To start IND…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Patients treated with BIV201 experienced reduced ascites fluid buildup (p CARSON CITY, Nev., March 13,…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…
First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (“First Wave…
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human Resources HAIFA, Israel, March…
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity
Chen Franco-Yehuda Chief Financial Officer Efrat Livne-Hadass Vice President of Human Resources HAIFA, Israel, March…
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive –Validation of TGFβ2 as therapeutic target AGOURA HILLS,…
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive –Validation of TGFβ2 as therapeutic target AGOURA HILLS,…
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were…
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
The study achieved high uptake of AR-501 in the respiratory tract at levels that were…
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and…
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and…
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the…